Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Editorial Commentary ◽

Randomised Controlled

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30735-1 ◽

2020 ◽

Vol 21 (1) ◽

pp. 95-104 ◽

Cited By ~ 22

Author(s):

Brian I Rini ◽

Sumanta K Pal ◽

Bernard J Escudier ◽

Michael B Atkins ◽

Thomas E Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Randomised Controlled

TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma

SSRN Electronic Journal ◽

10.2139/ssrn.3427299 ◽

2019 ◽

Author(s):

Brian Rini ◽

Sumanta K. Pal ◽

Bernard J. Escudier ◽

Michael B. Atkins ◽

Thomas E. Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2013.11.007 ◽

2014 ◽

Vol 12 (3) ◽

pp. 167-177.e2 ◽

Cited By ~ 19

Author(s):

David S. Hong ◽

Michael S. Gordon ◽

Wolfram E. Samlowski ◽

Razelle Kurzrock ◽

Nizar Tannir ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Open Label Study ◽

A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps4598 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS4598-TPS4598 ◽

Cited By ~ 16

Author(s):

Toni K. Choueiri ◽

Andrea B. Apolo ◽

Thomas Powles ◽

Bernard Escudier ◽

Osvaldo Rudy Aren ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

Annals of Oncology ◽

10.1093/annonc/mdq651 ◽

2011 ◽

Vol 22 (8) ◽

pp. 1812-1823 ◽

Cited By ~ 97

Author(s):

J. Beck ◽

G. Procopio ◽

E. Bajetta ◽

U. Keilholz ◽

S. Negrier ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Community Settings ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Expanded Access ◽

Diverse Community

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00693-8 ◽

2022 ◽

Author(s):

David Cella ◽

Robert J Motzer ◽

Cristina Suarez ◽

Steven I Blum ◽

Flavia Ejzykowicz ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Patient Reported Outcomes ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Patient Reported

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(19)30723-8 ◽

2019 ◽

Vol 393 (10189) ◽

pp. 2404-2415 ◽

Cited By ~ 233

Author(s):

Brian I Rini ◽

Thomas Powles ◽

Michael B Atkins ◽

Bernard Escudier ◽

David F McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Randomised Controlled Trial ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer ◽

10.1002/cncr.33033 ◽

2020 ◽

Vol 126 (18) ◽

pp. 4156-4167 ◽

Cited By ~ 6

Author(s):

Robert J. Motzer ◽

Bernard Escudier ◽

Saby George ◽

Hans J. Hammers ◽

Sandhya Srinivas ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Long Term Follow Up

254 A SUBANALYSIS OF PATIENTS WITH AND WITHOUT PRIOR NEPHRECTOMY IN A LARGE OPEN-LABEL, NON-COMPARATIVE PHASE 3 EUROPEAN ADVANCED RENAL CELL CARCINOMA (RCC) SORAFENIB STUDY (EU-ARCCS)

European Urology Supplements ◽

10.1016/s1569-9056(09)60259-1 ◽

2009 ◽

Vol 8 (4) ◽

pp. 184 ◽

Cited By ~ 1

Author(s):

M. Staehler ◽

G. Procopio ◽

U. Keilholz ◽

S. Negrier ◽

C. Szczylik ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Phase 3

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-005-0070-z ◽

2005 ◽

Vol 57 (4) ◽

pp. 533-539 ◽

Cited By ~ 38

Author(s):

Monika Jermann ◽

Rolf A Stahel ◽

Marc Salzberg ◽

Thomas Cerny ◽

Markus Joerger ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Locally Advanced ◽

Open Label ◽

Open Label Study ◽